CL2017002229A1 - Inhibidores de bace1. - Google Patents

Inhibidores de bace1.

Info

Publication number
CL2017002229A1
CL2017002229A1 CL2017002229A CL2017002229A CL2017002229A1 CL 2017002229 A1 CL2017002229 A1 CL 2017002229A1 CL 2017002229 A CL2017002229 A CL 2017002229A CL 2017002229 A CL2017002229 A CL 2017002229A CL 2017002229 A1 CL2017002229 A1 CL 2017002229A1
Authority
CL
Chile
Prior art keywords
present
bace1 inhibitors
bace1
alzheimer
therapeutic
Prior art date
Application number
CL2017002229A
Other languages
English (en)
Inventor
Cosimo Dolente
Bjoern Bartels
Wolfgang Guba
Wolfgang Haap
Sander Ulrike Obst
Jens-Uwe Peters
Thomas Woltering
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of CL2017002229A1 publication Critical patent/CL2017002229A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

<p>La presente invención proporciona un compuesto de fórmula I, que presenta una actividad inhibidora de BACE1, su preparación, composiciones farmacéuticas que los contienen y su utilización como sustancias terapéuticamente activas. Los compuestos activos de la presente invención resultan útiles en el tratamiento terapéutico y/o profiláctico de, por ejemplo, la enfermedad de Alzheimer.</p>
CL2017002229A 2015-03-20 2017-09-04 Inhibidores de bace1. CL2017002229A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP15160101 2015-03-20

Publications (1)

Publication Number Publication Date
CL2017002229A1 true CL2017002229A1 (es) 2018-04-13

Family

ID=52780400

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2017002229A CL2017002229A1 (es) 2015-03-20 2017-09-04 Inhibidores de bace1.

Country Status (18)

Country Link
US (4) US10047081B2 (es)
EP (1) EP3271355B1 (es)
JP (1) JP6674960B2 (es)
KR (1) KR20170129745A (es)
CN (1) CN107406440B (es)
AU (1) AU2016236402B2 (es)
BR (1) BR112017015474A2 (es)
CA (1) CA2979113A1 (es)
CL (1) CL2017002229A1 (es)
CO (1) CO2017007691A2 (es)
CR (1) CR20170426A (es)
IL (1) IL253322A0 (es)
MX (1) MX2017012188A (es)
PE (1) PE20171349A1 (es)
PH (1) PH12017501668A1 (es)
RU (1) RU2712272C2 (es)
SG (1) SG11201707050VA (es)
WO (1) WO2016150785A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2979113A1 (en) 2015-03-20 2016-09-29 F. Hoffmann-La Roche Ag Bace1 inhibitors
CN110467611B (zh) * 2018-05-11 2022-09-27 广东东阳光药业有限公司 亚氨基噻二嗪二氧化物衍生物及其用途
PY1943991A (es) 2018-06-06 2020-03-09 Syngenta Crop Protection Ag Derivados heterocíclicos con sustituyentes que contienen azufre activos como plaguicidas

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19962924A1 (de) 1999-12-24 2001-07-05 Bayer Ag Substituierte Oxazolidinone und ihre Verwendung
CN101952260B (zh) 2008-02-18 2013-02-13 弗·哈夫曼-拉罗切有限公司 4,5-二氢-*唑-2-基胺衍生物
US8461160B2 (en) 2009-05-08 2013-06-11 Hoffmann-La Roche, Inc. Dihydropyrimidinones
US8188079B2 (en) 2009-08-19 2012-05-29 Hoffman-La Roche Inc. 3-amino-5-phenyl-5,6-dihydro-2H-[1,4]oxazines
US20110065695A1 (en) 2009-09-11 2011-03-17 Jeremy Beauchamp Use of aminodihydrothiazines for the treatment or prevention of diabetes
US7964594B1 (en) 2009-12-10 2011-06-21 Hoffmann-La Roche Inc. Amino oxazine derivatives
UA103272C2 (uk) 2009-12-11 2013-09-25 Ф. Хоффманн-Ля Рош Аг 2-аміно-5,5-дифтор-5,6-дигідро-4h-оксазини як інгібітори bace1 і/або bace2
US8673894B2 (en) 2010-05-07 2014-03-18 Hoffmann-La Roche Inc. 2,5,6,7-tetrahydro-[1,4]oxazepin-3-ylamine or 2,3,6,7-tetrahydro-[1,4]oxazepin-5-ylamine compounds
US8815881B2 (en) 2010-08-09 2014-08-26 Hoffmann-La Roche Inc. 1,4,5,6-tetrahydro-pyrimidin-2-ylamine compounds
US20120053200A1 (en) 2010-09-01 2012-03-01 Harald Mauser Bace 2 inhibitors
US9242943B2 (en) 2011-01-18 2016-01-26 Siena Biotech S.P.A. 1,4 oxazines as BACE1 and/or BACE2 inhibitors
US8399459B2 (en) 2011-02-02 2013-03-19 Hoffmann-La Roche Inc. 1,4 oxazines as BACE1 and/or BACE2 inhibitors
US8404680B2 (en) 2011-02-08 2013-03-26 Hoffmann-La Roche Inc. N-[3-(5-amino-3,3a,7,7a-tetrahydro-1H-2,4-dioxa-6-aza-inden-7-yl)-phenyl]-amides as BACE1 and/or BACE2 inhibitors
US8815841B2 (en) 2011-02-18 2014-08-26 Hoffmann-La Roche Inc. 1,4-Oxazepines as BACE1 and/or BACE2 inhibitors
US9067924B2 (en) 2011-03-04 2015-06-30 Hoffmann-La Roche Inc. 1,4 thiazepines/sulfones as BACE1 and/or BACE2 inhibitors
US8748418B2 (en) 2011-03-18 2014-06-10 Hoffmann-La Roche Inc. 1,4-oxazepines as BACE1 and/or BACE2 inhibitors
US8877744B2 (en) 2011-04-04 2014-11-04 Hoffmann-La Roche Inc. 1,4-Oxazepines as BACE1 and/or BACE2 inhibitors
US8754075B2 (en) 2011-04-11 2014-06-17 Hoffmann-La Roche Inc. 1,3-oxazines as BACE1 and/or BACE2 inhibitors
BR112013026341A2 (pt) 2011-04-13 2019-09-24 Merck Sharp & Dohe Corp. composto, composição farmacêutica, e, método para tratar, prevenir e/ou atrasar o início de uma doença ou patologia
US8785436B2 (en) 2011-05-16 2014-07-22 Hoffmann-La Roche Inc. 1,3-oxazines as BACE 1 and/or BACE2 inhibitors
US9079919B2 (en) 2011-05-27 2015-07-14 Hoffmann-La Roche Inc. Spiro-[1,3]-oxazines and spiro-[1,4]-oxazepines as BACE1 and/or BACE2 inhibitors
EP2718287A1 (en) 2011-06-07 2014-04-16 F.Hoffmann-La Roche Ag [1,3]oxazines
AU2012266544A1 (en) 2011-06-07 2013-11-21 F. Hoffmann-La Roche Ag Halogen-alkyl-1,3 oxazines as BACE1 and/or BACE2 inhibitors
US8927535B2 (en) 2011-07-06 2015-01-06 Hoffman-La Roche Inc. Cyclopropyl-fused-1,3-thiazepines as BACE1 and/or BACE2 inhibitors
RU2014111055A (ru) * 2011-08-22 2015-09-27 Мерк Шарп И Доум Корп. 2-спирозамещенные иминотиазины и их моно- и диоксиды в качестве ингибиторов bace, композиции и их применение
US20130073953A1 (en) 2011-09-21 2013-03-21 Timothy Onyenobi News headline screenshot viewing system
KR101669349B1 (ko) 2012-01-26 2016-10-25 에프. 호프만-라 로슈 아게 플루오로메틸-5,6-다이하이드로-4h-[1,3]옥사진
JP6251249B2 (ja) * 2012-05-24 2017-12-20 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Ｂａｃｅ１阻害薬としての５−アミノ［１，４］チアジン類
JP6251257B2 (ja) 2012-06-26 2017-12-20 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Ｂａｃｅ１阻害薬としてのジフルオロ−ヘキサヒドロ−シクロペンタオキサジニル類及びジフルオロ−ヘキサヒドロ−ベンゾオキサジニル類
EP2908825B1 (en) * 2012-10-17 2018-04-18 Merck Sharp & Dohme Corp. Tricyclic substituted thiadiazine dioxide compounds as bace inhibitors, compositions, and their use
CN104968660A (zh) 2013-01-22 2015-10-07 霍夫曼-拉罗奇有限公司 作为bace1抑制剂的氟-[1,3]噁嗪类化合物
US9422255B2 (en) * 2013-03-15 2016-08-23 Merck Sharp & Dohme Corp. S-imino-S-oxo-iminothiazine compounds as BACE inhibitors, compositions, and their use
WO2014150340A1 (en) 2013-03-15 2014-09-25 Merck Sharp & Dohme Corp. S-imino-s-oxo iminothiadiazine compounds as bace inhibitors, compositions, and their use
US9453034B2 (en) 2013-03-15 2016-09-27 Merck Sharp & Dohme Corp. C2-azaspiro iminothiazine dioxides as BACE inhibitors, compositions, and their use
CA2979113A1 (en) 2015-03-20 2016-09-29 F. Hoffmann-La Roche Ag Bace1 inhibitors

Also Published As

Publication number Publication date
US20200308166A1 (en) 2020-10-01
JP2018507879A (ja) 2018-03-22
AU2016236402A1 (en) 2017-07-27
JP6674960B2 (ja) 2020-04-01
PE20171349A1 (es) 2017-09-13
WO2016150785A1 (en) 2016-09-29
US10723729B2 (en) 2020-07-28
US20190337936A1 (en) 2019-11-07
AU2016236402B2 (en) 2019-08-01
EP3271355A1 (en) 2018-01-24
US20180057485A1 (en) 2018-03-01
MX2017012188A (es) 2017-12-15
SG11201707050VA (en) 2017-10-30
US11034687B2 (en) 2021-06-15
BR112017015474A2 (pt) 2018-01-30
KR20170129745A (ko) 2017-11-27
EP3271355B1 (en) 2020-07-29
CO2017007691A2 (es) 2017-10-20
RU2712272C2 (ru) 2020-01-28
CN107406440B (zh) 2021-05-07
US10047081B2 (en) 2018-08-14
PH12017501668A1 (en) 2018-03-19
HK1244790A1 (zh) 2018-08-17
IL253322A0 (en) 2017-09-28
RU2017134884A (ru) 2019-04-22
US20180319787A1 (en) 2018-11-08
RU2017134884A3 (es) 2019-07-17
CA2979113A1 (en) 2016-09-29
CR20170426A (es) 2017-10-23
CN107406440A (zh) 2017-11-28
US10399969B2 (en) 2019-09-03

Similar Documents

Publication Publication Date Title
CR20200312A (es) Nuevas piridopirimidinonas sustituidas con bencilamino y derivados como inhibidores de sos1
CU20160109A7 (es) Compuestos de indazol como inhibidores de irak4
MX2015008957A (es) Fluoro-[1,3]oxazinas como inhibidores de beta-secretasa 1 (bace1).
CO2017004525A2 (es) Dihidropirrolopiridinas inhibidoras de ror-gamma
BR112018005497A2 (pt) compostos heterocíclicos e usos dos mesmos
ECSP13013068A (es) Halogenoalquil-1,3-oxazinas como inhibidores de la bace1 y/o bace2
ECSP13013024A (es) 1,3-oxazinas como inhibidores de bace1 y/o bace2
MX2017002656A (es) Compuestos que inhiben la proteína mcl-1.
CL2016002072A1 (es) 2-amino-3,5,5-trifluoro-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 para el tratamiento de la enfermedad de alzheimer
BR112017003054A2 (pt) compostos de aminopirimidinila como inibidores de jak
ECSP13013048A (es) Spiro-[1,3]-oxacinas y spiro-[1,4]-oxacepinas como inhibidores
EA201790170A1 (ru) Терапевтические соединения-ингибиторы
BR112016015838A8 (pt) compostos heterocíclicos aromáticos, composição farmacêutica compreendendo os referidos compostos e produto de combinação
MX2019012847A (es) Compuestos de c5-anilinoquinazolina y su uso en el tratamiento del cancer.
CL2016001918A1 (es) Heteroaril amidas como inhibidores de agregación de proteína
BR112015019412A2 (pt) inibidores de bace1
UA113538C2 (xx) Фторметил-5,6-дигідро-4h-$1,3]оксазини
TR201900148T4 (tr) Kansere karşı yeni maddeler olarak sübstitüe edilmiş 2,4 diamino-kinolin.
CO7151509A2 (es) Difluoro-hexahidro-ciclopentaoxacinilos y difluoro-hexahidro-benzooxacinilos como inhibidores de bace1
CO7131369A2 (es) 5-amino[1,4]tiazinas como inhibidores de bace1
EA201891319A1 (ru) Соединения алкилдигидрохинолинсульфонамида
CR20170426A (es) Inhibidores de bace 1
DOP2016000325A (es) Compuestos, composición farmacéutica y su uso en el tratamiento de enfermedades neurodegenerativas
MX384394B (es) Compuesto para uso en la prevención y tratamiento de enfermedades neurodegenerativas.
MX2016016061A (es) 2,2,2-trifluoroetil-tiadiazinas.